Why NeuroMetrix (NURO) Stock Is Surging Today

NEW YORK (TheStreet) -- NeuroMetrix  (NURO) surged Tuesday after the medical technology developer reported Japanese regulatory approval for NC-stat DPNCheck.

The company announced it had received marketing certification from Technischer Uberwachungs-Verein SUD Japan for NC-stat DPNCheck as a Class II Designated Controlled Medical Device based on the technical standards of the Japan Ministry of Health, Labor, and Welfare. NC-stat DPNCheck is a test designed to detect diabetic peripheral neuropathy, or DPN, at an early stage.

Omron Healthcare is the exclusive distributor for NeuroMetrix in Japan and will distribute NC-stat DPNCheck in the nation.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 26% to $2.37 at 12:19 p.m. More than 1.8 million shares had changed hands, which dwarfed the average volume of 62,722.

NURO Chart

NURO data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

The 7 Most Intriguing Products We Saw at CES

The 7 Most Intriguing Products We Saw at CES

NeuroMetrix (NURO) Stock Gains After Launching Diabetes Test in Mexico

NeuroMetrix (NURO) Stock Gains After Launching Diabetes Test in Mexico

Insider Trading Alert - CMPR, AER And NURO Traded By Insiders

Insider Trading Alert - CMPR, AER And NURO Traded By Insiders

Insider Trading Alert - SKT, HEB And NURO Traded By Insiders

Insider Trading Alert - SKT, HEB And NURO Traded By Insiders

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar